Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
September 12, 2023
- New MHLW Drug Review Chief Vows to Make Japan Attractive Place for Clinical Trials, Watching Debate on Japanese PI
September 12, 2023
- New Working Group to Propose Effective Collection and Sharing of Drug Supply Info by March-End
September 12, 2023
- Japan to End Free COVID Vaccine Program in March, Weighs NIP Inclusion
September 11, 2023
- Japan Panel OKs Use of Pfizer’s XBB.1.5 Jab for Fall Vaccination Campaign
September 11, 2023
- PMDA Reviewing Safety Risks for G-CSF Agents, Yervoy and More
September 11, 2023
- MHLW Panel OKs Changes to Guidelines for Using NDB, Anonymized Medical Data
September 11, 2023
- Japan Mulling Once-a-Year COVID Booster for Elderly in FY2024
September 8, 2023
- MHLW Moving Toward Allowing Use of Cannabis-Derived Drugs: LDP Session
September 8, 2023
- LDP Lawmakers Deplore Reported GMP Issues at Sawai
September 8, 2023
- MHLW Plans to Consolidate Class 2 and 3 OTC Drugs
September 7, 2023
- Exact Sciences’ SaMD to Assess Breast Cancer Recurrence Risk Listed on Sept. 1
September 7, 2023
- Japan Eyes AI-Driven Drug Discovery Project for Cancer, Intractable Diseases
September 7, 2023
- Japan Unveils 2nd Package Strategy for SaMD
September 7, 2023
- Japan Healthcare Spending Renews Record with 46 Trillion Yen in FY2022
September 6, 2023
- Japan to Soon Start Taking Applications for Antibiotic Revenue Guarantee Program
September 6, 2023
- MHLW to Launch Working Group on Drug Supply Info on Sept. 7
September 5, 2023
- 23 Suspected Violations in Promotion Activities Reported in FY2022: MHLW
September 5, 2023
- Dispensing Pharmacy Chief Nabbed for Obstruction of Public Bid
September 4, 2023
- Japan Launches Agency for Infectious Disease Crisis Management
September 4, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…